These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 18348679)

  • 21. Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems.
    Brichta L; Greengard P; Flajolet M
    Trends Neurosci; 2013 Sep; 36(9):543-54. PubMed ID: 23876424
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plausible improvements for selective targeting of dopamine receptors in therapy of Parkinson's disease.
    Luthra PM; Kumar JB
    Mini Rev Med Chem; 2012 Dec; 12(14):1556-64. PubMed ID: 22697513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Therapeutic and pharmacologic perspectives in Parkinson's disease].
    Corvol JC; Mariani LL
    Rev Prat; 2018 May; 68(5):515-519. PubMed ID: 30869416
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Non-dopaminergic treatments for Parkinson's disease].
    Derkinderen P
    Rev Neurol (Paris); 2010 Oct; 166(10):811-5. PubMed ID: 20832090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials.
    Kalia LV; Brotchie JM; Fox SH
    Mov Disord; 2013 Feb; 28(2):131-44. PubMed ID: 23225267
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Noradrenaline in Parkinson's disease: from disease progression to current therapeutics.
    Fornai F; di Poggio AB; Pellegrini A; Ruggieri S; Paparelli A
    Curr Med Chem; 2007; 14(22):2330-4. PubMed ID: 17896981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New pharmacologic horizons in the treatment of Parkinson disease.
    Bonuccelli U; Del Dotto P
    Neurology; 2006 Oct; 67(7 Suppl 2):S30-8. PubMed ID: 17030738
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reevaluation of levodopa therapy for the treatment of advanced Parkinson's disease.
    Yokochi M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S25-30. PubMed ID: 19131038
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Chase TN
    Drugs; 1998; 55 Suppl 1():1-9. PubMed ID: 9483164
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent developments in the pharmacological treatment of Parkinson's disease.
    Tuite P; Riss J
    Expert Opin Investig Drugs; 2003 Aug; 12(8):1335-52. PubMed ID: 12882620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current concepts in clinical therapeutics: Parkinson's disease.
    Erwin WG; Turco TF
    Clin Pharm; 1986 Sep; 5(9):742-53. PubMed ID: 3530616
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease.
    Fariello RG
    Drugs; 1998; 55 Suppl 1():10-6. PubMed ID: 9483165
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Is the inhibition of adenosine A(2A) receptors an efficient way of Parkinson's disease treatment?].
    Ceiślak M; Komoszyński M
    Neurol Neurochir Pol; 2006; 40(3):219-26. PubMed ID: 16794962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of early Parkinson's disease.
    Hauser RA; Zesiewicz TA
    Med Clin North Am; 1999 Mar; 83(2):393-414, vi. PubMed ID: 10093585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiparkinsonian drugs and their neuroprotective effects.
    Kitamura Y; Kakimura J; Taniguchi T
    Biol Pharm Bull; 2002 Mar; 25(3):284-90. PubMed ID: 11913520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
    Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
    Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The treatment of Parkinson's disease--adenosine A2A receptor antagonists].
    Matsubara E; Shoji M; Abe K
    Nihon Rinsho; 2002 Jan; 60(1):112-6. PubMed ID: 11808320
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Are dopamine receptor agonists neuroprotective in Parkinson's disease?
    Le WD; Jankovic J
    Drugs Aging; 2001; 18(6):389-96. PubMed ID: 11419913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progress of Pharmacological Approaches in Parkinson's Disease.
    Zeuner KE; Schäffer E; Hopfner F; Brüggemann N; Berg D
    Clin Pharmacol Ther; 2019 May; 105(5):1106-1120. PubMed ID: 30661251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel models for Parkinson's disease and their impact on future drug discovery.
    Trigo-Damas I; Del Rey NL; Blesa J
    Expert Opin Drug Discov; 2018 Mar; 13(3):229-239. PubMed ID: 29363335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.